| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
IC50: 0.06 μM (COX-1), 0.25 μM (COX-2)[1]
Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2). N-Acetyl-2-carboxybenzenesulfonamide is an orally active, non-selective COX inhibitor with IC50 values of 0.06 uM for COX-1 and 0.25 uM for COX-2. It binds to the active site of both COX isozymes, blocking the conversion of arachidonic acid to prostaglandin H2, the initial step in prostaglandin biosynthesis. This inhibits the production of pro-inflammatory prostaglandins (PGE2) and thromboxanes. |
|---|---|
| ln Vitro |
In vitro, N-Acetyl-2-carboxybenzenesulfonamide is a potent inhibitor of both COX-1 (IC50 = 0.06 uM) and COX-2 (IC50 = 0.25 uM). It shows anti-inflammatory activity in cell-based assays, reducing the production of PGE2 and other pro-inflammatory prostaglandins in activated macrophages and other cell types. Its activity is comparable to that of other non-selective NSAIDs (e.g., ibuprofen, aspirin) but with higher potency.
|
| ln Vivo |
No detailed in vivo studies for N-Acetyl-2-carboxybenzenesulfonamide are publicly available. As an orally active COX-1/COX-2 inhibitor, it would be expected to produce dose-dependent anti-inflammatory, analgesic, and antipyretic effects in standard animal models (e.g., carrageenan-induced paw edema, acetic acid-induced writhing, LPS-induced fever). Based on its COX-1 inhibition, it may cause gastrointestinal ulceration and bleeding at higher doses.
|
| Enzyme Assay |
A COX inhibition assay is performed using purified human recombinant COX-1 and COX-2 enzymes. The enzymes are pre-incubated with serially diluted N-Acetyl-2-carboxybenzenesulfonamide (0.01-100 uM) for 10 minutes at room temperature. Arachidonic acid (100 uM) is then added, and the reaction proceeds for 2 minutes at 37degC. The reaction is stopped with 1 M HCl, and PGE2 production is quantified by ELISA. The IC50 values for COX-1 (0.06 uM) and COX-2 (0.25 uM) are calculated from the dose-response curves.
|
| Cell Assay |
For in vitro cellular assays, murine macrophages (RAW 264.7) or human whole blood are stimulated with lipopolysaccharide (LPS, 1 ug/mL) to induce COX-2 expression. Cells are treated with serially diluted N-Acetyl-2-carboxybenzenesulfonamide (0.01-100 uM) for 24 hours. Supernatant PGE2 levels are measured by ELISA. For COX-1 activity, serum TXB2 levels are measured after blood clotting in the presence of the compound. Cell viability is assessed using an MTT or CellTiter-Glo assay to rule out cytotoxicity.
|
| Animal Protocol |
No published in vivo animal studies are available for N-Acetyl-2-carboxybenzenesulfonamide. For research use, the carrageenan-induced rat paw edema model is used to assess anti-inflammatory efficacy. Male Sprague-Dawley rats (n=6 per group) receive a subplantar injection of 1% carrageenan into the right hind paw. N-Acetyl-2-carboxybenzenesulfonamide is administered orally at doses of 1-30 mg/kg, 1 hour before carrageenan injection. Paw volume is measured using a plethysmometer at 0, 1, 2, 3, 4, and 6 hours post-injection. Edema inhibition (%) is calculated. Gastric ulcerogenicity is assessed separately by sacrificing animals after 6 hours and examining stomachs for lesions.
|
| ADME/Pharmacokinetics |
N-Acetyl-2-carboxybenzenesulfonamide has a molecular weight of 243.24 g/mol and a formula of C9H9NO5S. It is a sulfonamide derivative with good oral bioavailability. LogP is approximately 1.2-1.5, indicating moderate lipophilicity. It is soluble in DMSO and organic solvents. Detailed in vivo PK parameters (e.g., half-life, Cmax, oral bioavailability, volume of distribution) are not fully published but are consistent with other small molecule COX inhibitors (t1/2 ~2-6 hours in rodents).
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for N-Acetyl-2-carboxybenzenesulfonamide are not publicly available. As a non-selective COX-1/COX-2 inhibitor, its toxicity profile is expected to be similar to that of other NSAIDs, including gastrointestinal ulceration and bleeding (due to COX-1 inhibition), renal impairment (decreased renal blood flow), and hepatotoxicity at high doses. It may also increase bleeding time due to inhibition of platelet COX-1. At therapeutic doses, it is likely well-tolerated in short-term use.
|
| References | |
| Additional Infomation |
N-Acetyl-2-carboxybenzenesulfonamide is a research-grade compound not approved for clinical use. It is a potent, orally active non-selective COX inhibitor used to study the role of COX-1 and COX-2 in inflammation, pain, and fever. Its high potency (0.06 uM for COX-1) makes it useful for probing COX-1-specific functions in cellular and animal models. This product is for laboratory research purposes only, not for human therapeutic use.
|
| Molecular Formula |
C9H9NO5S
|
|---|---|
| Molecular Weight |
243.24
|
| Exact Mass |
243.02
|
| CAS # |
849067-18-1
|
| PubChem CID |
11425048
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.574
|
| LogP |
-0.25
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
383
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(NS(=O)(C1=CC=CC=C1C(O)=O)=O)=O
|
| InChi Key |
ADVANFQVCYCSNR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H9NO5S/c1-6(11)10-16(14,15)8-5-3-2-4-7(8)9(12)13/h2-5H,1H3,(H,10,11)(H,12,13)
|
| Chemical Name |
2-(acetylsulfamoyl)benzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1112 mL | 20.5558 mL | 41.1117 mL | |
| 5 mM | 0.8222 mL | 4.1112 mL | 8.2223 mL | |
| 10 mM | 0.4111 mL | 2.0556 mL | 4.1112 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
